JIPLP: Insufficiency finally upheld as ground for invalidity of antibody claim

No items found.
​
21 October 2013
Tags
Litigation
Life
Table of contents
  • Toc Heading
  • Toc Heading

The Journal of Intellectual Property Law and Practice has published an article by partner Darren Smyth about the judgement in Eli Lilly & Company v Janssen Alzheimer Immunotherapy.

Mr Justice Arnold determines that a patent directed towards antibodies to ß-amyloid peptide, for the treatment of Alzheimer's disease, is invalid for insufficiency.

To read the JIPLP article in full, click here.

Related articles

See all articles

EIP welcomes Anders Hansson as Partner to further strengthen our digital practice
19 January 2026
EIP is pleased to welcome Anders Hansson as Partner, bringing nearly 20 years of experience in AI, robotics, digital technologies, and European patent strategy. His industry and private‑practice background further strengthens our digital and high‑tech capabilities across Europe.
​
EIP Recognised in The Times Best Law Firms 2026
03 December 2025
EIP is proud to be featured in The Times Best Law Firms 2026, a prestigious list based on peer recommendations across the legal industry. This recognition highlights EIP’s commitment to technical excellence, client-focused service, and innovative IP strategies. From high-value patent litigation to strategic portfolio management, EIP continues to deliver results that matter for clients in technology, life sciences, and engineering. This accolade reinforces our position as a trusted leader in intellectual property law.
​
EIP Launches Tech & AI Function to Drive Innovation and Client Excellence
06 November 2025
When it comes to technology, EIP has always been ahead of the curve; we are proud to announce the evolution of our IT department into a dedicated Tech & AI function, marking a bold step towards...
​